Illumina, Inc. (NASDAQ:ILMN) Receives $167.70 Average Price Target from Analysts

Shares of Illumina, Inc. (NASDAQ:ILMN) have earned a consensus rating of “Hold” from the nineteen ratings firms that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and eight have issued a buy rating on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $167.70.

A number of research firms have issued reports on ILMN. TD Cowen downgraded shares of Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 target price for the company. in a research report on Thursday, January 4th. OTR Global restated a “mixed” rating on shares of Illumina in a research note on Wednesday, March 20th. Barclays increased their price target on shares of Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a research note on Wednesday, April 10th. Stephens restated an “overweight” rating and set a $170.00 price target on shares of Illumina in a research note on Wednesday, April 10th. Finally, StockNews.com upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research note on Friday, February 16th.

Illumina Stock Up 2.4 %

ILMN stock opened at $120.25 on Friday. Illumina has a 12-month low of $89.00 and a 12-month high of $229.58. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.26. The company has a market cap of $19.15 billion, a price-to-earnings ratio of -16.38 and a beta of 1.19. The company has a 50 day moving average of $132.98 and a two-hundred day moving average of $127.68.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter in the prior year, the firm earned $0.14 EPS. The company’s revenue was up 3.6% compared to the same quarter last year. On average, equities analysts anticipate that Illumina will post 0.91 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Jacob Thaysen purchased 7,330 shares of the firm’s stock in a transaction on Thursday, February 22nd. The shares were bought at an average cost of $135.29 per share, for a total transaction of $991,675.70. Following the transaction, the chief executive officer now directly owns 14,861 shares of the company’s stock, valued at approximately $2,010,544.69. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.17% of the company’s stock.

Hedge Funds Weigh In On Illumina

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Bouvel Investment Partners LLC lifted its holdings in shares of Illumina by 1.3% during the 1st quarter. Bouvel Investment Partners LLC now owns 6,547 shares of the life sciences company’s stock worth $899,000 after acquiring an additional 84 shares during the period. STF Management LP lifted its holdings in shares of Illumina by 3.5% during the 4th quarter. STF Management LP now owns 2,644 shares of the life sciences company’s stock worth $368,000 after acquiring an additional 90 shares during the period. Gulf International Bank UK Ltd lifted its holdings in shares of Illumina by 0.7% during the 1st quarter. Gulf International Bank UK Ltd now owns 13,562 shares of the life sciences company’s stock worth $1,862,000 after acquiring an additional 98 shares during the period. Eukles Asset Management lifted its holdings in shares of Illumina by 1.7% during the 3rd quarter. Eukles Asset Management now owns 5,942 shares of the life sciences company’s stock worth $816,000 after acquiring an additional 100 shares during the period. Finally, Clear Creek Financial Management LLC lifted its holdings in shares of Illumina by 6.3% during the 4th quarter. Clear Creek Financial Management LLC now owns 1,695 shares of the life sciences company’s stock worth $236,000 after acquiring an additional 100 shares during the period. 89.42% of the stock is owned by institutional investors.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.